Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.

Authors

• Jordan M Winter
• Charles J Yeo
• Jonathan R Brody

Publication/Presentation Date

1-1-2013

Abstract

Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens.

Volume

107

Issue

1

First Page

15

Last Page

22

ISSN

1096-9098

Published In/Presented At

Winter, J. M., Yeo, C. J., & Brody, J. R. (2013). Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. Journal of surgical oncology, 107(1), 15–22. https://doi.org/10.1002/jso.23192

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

22729569

Department(s)

Administration and Leadership

Document Type

Article